LRMR
Larimar Therapeutics, Inc.
Key Financials
Operating Income
$-172497000
↓ 89.8%
Revenue
$0
NaN%
Total Liabilities
$67.8M
↑ 138.5%
EPS (Diluted)
$-1.32
↓ 57.1%
Shareholders' Equity
$78.1M
↓ 54.6%
Long-term Debt
$14.5M
↓ 27.3%
Net Income
$-165673000
↓ 105.5%
Cash & Equivalents
$85.4M
↑ 157.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/4/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 4 | 7/8/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LRMR |
| Company Name | Larimar Therapeutics, Inc. |
| CIK | 1374690 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 844-511-9056 |